'MyBioPharmaSpace'

People in New Zealand living with chronic lymphocytic leukaemia may soon gain funded access to modern targeted therapies under a new proposal from Pharmac.

Percheron Therapeutics (ASX:PER) is positioning itself as a small but strategically focused biotechnology company seeking to carve out a role in the rapidly expanding immuno-oncology market.

As global health leaders gather in Sydney for this week’s Global Antimicrobial Resistance Summit, one message is clear. The world is running out of time to address the growing threat of antibiotic-resistant infections.

Recently elected Opposition Leader Angus Taylor has confirmed that South Australian senator Anne Ruston will remain responsible for the health and aged care portfolio, signalling continuity in the Coalition’s approach to two of the country's most politically sensitive policy areas.

The proposal, led by Advanced Pharmacy Australia, argues that medicine shortages are no longer isolated incidents but a persistent structural challenge for the health system.

Australia’s PBS decision-making framework was built to make difficult decisions fairly, in theory. The reality is that decisions made ethically consistent within this framework can produce outcomes that are intrinsically unethical because of their intolerable human impact. At that point, where the consequence is suffering or death, they become immoral.

The PBS has come under renewed scrutiny in Washington after the U.S. pharmaceutical industry used a submission to call for Australia’s inclusion on its Priority Watch List.

Health Minister Mark Butler has confirmed that the Albanese Government has approved new and expanded Pharmaceutical Benefits Scheme listings to improve access to treatments for Australians living with cystic fibrosis, chronic kidney disease, and psoriasis.

Remuneration for board directors in Australia’s listed healthcare and biotechnology sector increased materially in the financial year 2025, with growth driven largely by the expanding use of equity-based incentives rather than increases in base fees.

The life sciences sector will come together in March 2026 for a major show of support for women’s leadership, as AusBiotech and Medicines Australia expand their partnership to deliver both the long-running Women in Life Sciences Luncheon and, for the first time, a dedicated Leadership Summit.

A new prostate cancer imaging technology from Clarity Pharmaceuticals (ASX:CU6) is showing promise in improving the detection of recurrent disease, after results from a comparative clinical study indicated it may outperform the current standard of care.

Emyria’s (ASX:EMD) push to scale its insurer-backed mental health services across Australia has taken a significant step forward, with Medibank expanding its funding agreement to support patients at the company’s new Mornington Peninsula clinic in Victoria.